Skip to main content
Premium Trial:

Request an Annual Quote

FH Foundation, Invitae, Genome Medical Partner on Genetic Testing Initiative

NEW YORK (GenomeWeb) – The FH Foundation announced today the launch of the FIND HoFH (homozygous familial hypercholesterolemia) program to improve diagnosis for the condition by identifying people at risk.

HoFH is more severe than FH and can cause heart disease, heart attacks, and aortic valve disease in kids and adults. The disease impacts 1 in 300,000 Americans who inherit two mutations in FH genes. The disease can be diagnosed using clinical assessments and through genetic testing.

Individuals identified as needing HoFH evaluation will receive confirmatory genetic testing from Invitae and genetic counseling from the telegenetics firm Genome Medical.

Invitae's FH panel analyzes patients for mutations in APOB, LDLR, LDLRAP1, and PCSK9. While a negative test doesn't rule out HoFH, all those with HoFH have mutations in one of these genes. Individuals with the more common form of the condition, heterozygous FH, carry one copy of a disease-causing variant.

"FH is a treatable condition that is sadly underrecognized by the healthcare system," Genome Medical's Chief Medical Officer Steven Bleyl said in a statement. "With our nationwide telegenetics service, we see the opportunity to identify patients and educate both them and their personal physicians, hopefully leading to a ripple effect of greater awareness about this disease and improved health for patients."

Individuals will have the option to receive free genetic counseling and support for ordering and interpretation of genetic test results through Genome Medical's genetic navigation services.

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.